Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.33% to 5,693.31 and Dow Jones ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are covering the firm, MarketBeat Ratings reports.

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best diabetes stocks to buy according to billionaires. The WHO estimates that 422 million ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.